MedPath

A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis

Phase 3
Completed
Conditions
Rheumatoid Arthritis
Interventions
Other: Placebo
Biological: Certolizumab Pegol
Biological: Methotrexate
Registration Number
NCT01519791
Lead Sponsor
UCB Pharma SA
Brief Summary

This study is intended to evaluate the efficacy and safety of Certolizumab Pegol (CZP) in combination with Methotrexate (MTX) for inducing and sustaining clinical response in the treatment of Disease Modifying Antirheumatic Drug (DMARD)-naïve adults with early active Rheumatoid Arthritis.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
880
Inclusion Criteria
  • Subjects must have a time since diagnosis of adult-onset Rheumatoid Arthritis (RA) less than 1 year as defined by the 2010 ACR/EULAR classification criteria from Screening Visit
  • Positive Rheumatoid Factor (RF) and/or positive anticyclic Citrullinated Peptide Antibody (anti-CCP)
  • Active RA disease
  • DMARD-naïve
  • Subject is naïve to RA related biologics
Exclusion Criteria
  • A diagnosis of any other inflammatory Arthritis
  • History of infected joint prosthesis, or other significant infection and other serious medical condition
  • Known Tuberculosis (TB) disease or high risk of acquiring TB infection

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Placebo + MethotrexatePlacebo-
Certolizumab Pegol + MethotrexateCertolizumab Pegol-
Placebo + MethotrexateMethotrexate-
Certolizumab Pegol + MethotrexateMethotrexate-
Primary Outcome Measures
NameTimeMethod
Percentage of Subjects in Sustained Remission at Week 52Week 52

Sustained remission is defined as a Disease Activity Score \[Erythrocyte Sedimentation Rate\] (DAS28\[ESR\]) \< 2.6 at both Weeks 40 and 52.

DAS28\[ESR\] is calculated using the Tender Joint Count (TJC), Swollen Joint Count (SJC) Erythrocyte Sedimentation Rate (ESR in mm/hour), and the Patient's Global Assessment of Disease Activity - Visual Analog Scale (PtGADA-VAS in mm) using the following formula:

0.56 x √(TJC) + 0.28 x √(SJC) + 0.70 x lognat (ESR) + 0.014 x PtGADA, where 28 joints are examined and a lower score indicates less disease activity.

Secondary Outcome Measures
NameTimeMethod
Percentage of Subjects in Sustained Low Disease Activity (LDA) at Week 52Week 52

Sustained LDA is defined as a Disease Activity Score \[Erythrocyte Sedimentation Rate\] (DAS28\[ESR\]) ≤ 3.2 at both Weeks 40 and 52.

Change From Baseline in Modified Total Sharp Score (mTSS) to Week 52From Baseline (Week 0) to Week 52

Van der Heijde modified Total Sharp Score (mTSS) is a methodology to assess the degree of joint damage by quantifying the extent of bone erosions and joint space narrowing for 44 and 42 joints, respectively. The mTSS ranges from 0 to 448, with higher scores representing greater damage.

Percentage of Subjects With Radiographic Non-progression From Baseline to Week 52From Baseline (Week 0) to Week 52

Radiographic non-progression is defined as change in mTSS ≤ 0.5.

Change From Baseline in the Joint Erosion Score to Week 52From Baseline (Week 0) to Week 52

Erosions were assessed in 16 locations per hand and 6 joints per foot. Erosions for each hand location were scored from 0 to 5, with 0 indicating no erosion. Scores 1 to 5 may have included combinations of discrete erosion(s) and/or large erosions. Erosions for each foot joint were scored from 0 to 10, with 0 indicating no erosions.

The maximum possible erosion score for all 32-hand joints was 160. The maximum possible erosion score for all 12 feet joints was 120. Thus, the maximum possible total erosion score for hands and feet was 280.

Change From Baseline in the Joint Narrowing Score to Week 52From Baseline (Week 0) to Week 52

Joint space narrowing (JSN) was assessed in 15 locations per hand and 6 locations per foot. Joint space narrowing for each location was scored from 0 to 4, with 0 indicating no narrowing. The maximum possible score for JSN in all 30 hand joints was 120. The maximum possible score for JSN in all 12 feet joints was 48. Thus, the maximum possible total JSN score for Hands and feet was 168.

Percentage of Subjects Meeting the American College of Rheumatology 20 % Response Criteria (ACR20) at Week 52From Baseline (Week 0) to Week 52

The assessments are based on a 20 % or greater improvement from Baseline in the number of tender joints, a 20 % or more improvement in the number of swollen joints, and a 20% or greater improvement in 3 of the 5 remaining core set measures: Patient's Global Assessment of Disease Activity (PtGADA), Physician's Global Assessment of Disease Activity (PhGADA), Patient's Assessment of Arthritis Pain (PtAAP), physical function as assessed by the Health Assessment Questionnaire - Disability Index (HAQ-DI) and C-Reactive Protein (CRP).

Percentage of Subjects Achieving Low Disease Activity (LDA) at Week 52Week 52

LDA is defined as achieving a Disease Activity Score 28 \[Erythrocyte Sedimentation Rate\] (DAS28 \[ESR\]) ≤ 3.2.

Percentage of Subjects Meeting the American College of Rheumatology 50 % Response Criteria (ACR50) at Week 52From Baseline (Week 0) to Week 52

The assessments are based on a 50 % or greater improvement from Baseline in the number of tender joints, a 50 %, or more improvement in the number of swollen joints, and a 50 % or greater improvement in 3 of the 5 remaining core set measures: Patient's Global Assessment of Disease Activity (PtGADA), Physician's Global Assessment of Disease Activity (PhGADA), Patient's Assessment of Arthritis Pain (PtAAP), physical function as assessed by the Health Assessment Questionnaire - Disability Index (HAQ-DI) and C-Reactive Protein (CRP).

Percentage of Subjects Meeting the American College of Rheumatology 70 % Response Criteria (ACR70) at Week 52From Baseline (Week 0) to Week 52

The assessments are based on a 70 % or greater improvement from Baseline in the number of tender joints, a 70 %, or more improvement in the number of swollen joints, and a 70 % or greater improvement in 3 of the 5 remaining core set measures: Patient's Global Assessment of Disease Activity (PtGADA), Physician's Global Assessment of Disease Activity (PhGADA), Patient's Assessment of Arthritis Pain (PtAAP), physical function as assessed by the Health Assessment Questionnaire - Disability Index (HAQ-DI) and C-Reactive Protein (CRP).

Percentage of Subjects Meeting the 2011 American College of Rheumatology/ European League Against Rheumatism (ACR/EULAR) Remission Criteria at Week 52Week 52

The ACR/EULAR 2011 remission criteria is defined as:

Tender Joint Count (TJC) ≤ 1, Swollen Joint Count (SJC) ≤ 1, C-reactive protein (CRP) ≤ 1 mg/dl and Patient's Global Assessment of Disease Activity (PtGADA) ≤ 1.

Percentage of Subjects With Disease Activity Score 28 [Erythrocyte Sedimentation Rate] (DAS28 [ESR]) < 2.6 at Week 52Week 52

DAS28\[ESR\] is calculated using the Tender Joint Count (TJC), Swollen Joint Count (SJC) Erythrocyte Sedimentation Rate (ESR in mm/hour), and the Patient's Global Assessment of Disease Activity - Visual Analog Scale (PtGADA-VAS in mm) using the following formula:

0.56 x √(TJC) + 0.28 x √(SJC) + 0.70 x lognat (ESR) + 0.014 x PtGADA, where 28 joints are examined and a lower score indicates less disease activity.

Percentage of Subjects Meeting the 2011 American College of Rheumatology/ European League Against Rheumatism (ACR/EULAR) Remission Criteria Simplified for Clinical Practice at Week 52Week 52

The 2011 ACR/EULAR remission criteria simplified for clinical practice is defined as:

Tender Joint Count (TJC) ≤ 1, Swollen Joint Count (SJC) ≤ 1 and Patient's Global Assessment of Disease Activity (PtGADA) ≤ 1.

Change From Baseline in Disease Activity Score 28 [Erythrocyte Sedimentation Rate] (DAS28 [ESR]) to Week 52From Baseline (Week 0) to Week 52

DAS28\[ESR\] is calculated using the Tender Joint Count (TJC), Swollen Joint Count (SJC) Erythrocyte Sedimentation Rate (ESR in mm/hour), and the Patient's Global Assessment of Disease Activity - Visual Analog Scale (PtGADA-VAS in mm) using the following formula:

0.56 x √(TJC) + 0.28 x √(SJC) + 0.70 x lognat (ESR) + 0.014 x PtGADA, where 28 joints are examined and a lower score indicates less disease activity. A negative value in DAS28\[ESR\] change from Baseline indicates an improvement from Baseline.

Number of Work Days With Reduced Productivity (Work Productivity Survey - Rheumatoid Arthritis [WPS-RA]) at Week 52Week 52

Number of work days with reduced productivity in the last month for employed subjects.

Percentage of Subjects With Clinical Disease Activity Index (CDAI) ≤ 2.8 at Week 52Week 52

CDAI is calculated as the sum of tender joint count (TJC), swollen joint count (SJC), Patient's Global Assessment of Disease Activity - Visual Analog Scale (PtGADA-VAS in mm), and Physician's Global Assessment of Disease Activity - Visual Analog Scale (PhGADA-VAS in mm). 28 joints are examined where a lower score indicates less disease activity.

Percentage of Subjects With Simplified Disease Activity Index (SDAI) ≤ 3.3 at Week 52Week 52

SDAI is calculated as the sum of tender joint count (TJC), swollen joint count (SJC), Patient's Global Assessment of Disease Activity - Visual Analog Scale (PtGADA-VAS in mm), Physician's Global Assessment of Disease Activity - Visual Analog Scale (PhGADA-VAS in mm) and C-Reactive Protein (CRP in mg/L). 28 joints are examined where a lower score indicates less disease activity.

Percentage of Subjects Achieving a Good or Moderate European League Against Rheumatism (EULAR) Response at Week 52From Baseline (Week 0) to Week 52

Good response is defined as:

DAS28\[ESR\] ≤ 3.2 and decrease from Baseline by \> 1.2;

moderate response is defined as achievement of one of the following:

* DAS28\[ESR\] ≤ 3.2 and decrease from Baseline \> 0.6 and ≤ 1.2

* DAS28\[ESR\] \> 3.2 and ≤ 5.1 and decrease from Baseline \> 0.6

* DAS28\[ESR\] \> 5.1 and decrease from Baseline \>1.2.

Change From Baseline in Clinical Disease Activity Index (CDAI) to Week 52From Baseline (Week 0) to Week 52

CDAI is calculated as the sum of tender joint count (TJC), swollen joint count (SJC), Patient's Global Assessment of Disease Activity - Visual Analog Scale (PtGADA-VAS in mm), and Physician's Global Assessment of Disease Activity - Visual Analog Scale (PhGADA-VAS in mm). 28 joints are examined where a lower score indicates less disease activity.

The CDAI score ranges from 0 to 76, with a negative value in CDAI change from Baseline indicating an improvement from Baseline.

Change From Baseline in the Health Assessment Questionnaire - Disability Index (HAQ-DI) to Week 52From Baseline (Week 0) to Week 52

The domains of the HAQ-DI are dressing and grooming, arising, eating, walking, hygiene, reach, grip and common daily activities.

The total score ranges from 0 (no difficulty) to 3 (unable to do) with lower scores meaning lower disability.

A negative value in HAQ-DI change from Baseline indicates an improvement from Baseline.

Change From Baseline in Simplified Disease Activity Index (SDAI) to Week 52From Baseline (Week 0) to Week 52

SDAI is calculated as the sum of tender joint count (TJC), swollen joint count (SJC), Patient's Global Assessment of Disease Activity - Visual Analog Scale (PtGADA-VAS in mm), Physician's Global Assessment of Disease Activity - Visual Analog Scale (PhGADA-VAS in mm) and C-Reactive Protein (CRP in mg/L). 28 joints are examined where a lower score indicates less disease activity.

The SDAI score ranges from 0 to 86, with a negative value in SDAI change from Baseline indicating an improvement from Baseline.

Interference With Work Productivity (Work Productivity Survey - Rheumatoid Arthritis [WPS-RA]) at Week 52Week 52

The Arthritis interference in the last month with work productivity is measured on a scale that ranges from 0 (no interference) to 10 (complete interference) for employed subjects.

Number of Days With Reduced Household Work Productivity (Work Productivity Survey - Rheumatoid Arthritis [WPS-RA]) at Week 52Week 52

Number of days with reduced household work productivity in the last month.

Percentage of Subjects With a Health Assessment Questionnaire- Disability Index (HAQ-DI) ≤ 0.5 at Week 52Week 52

Normative physical function is defined as HAQ-DI score ≤ 0.5. The domains of the HAQ-DI are dressing and grooming, arising, eating, walking, hygiene, reach, grip and common daily activities.

The total score ranges from 0 to 3 with lower scores meaning lower disability.

Change From Baseline in the Bristol Rheumatoid Arthritis Fatigue- Multidimensional Questionnaire (BRAF-MDQ) Total Score to Week 52From Baseline (Week 0) to Week 52

BRAF-MDQ total score ranges from 0 to 70 (with higher scores indicating worse fatigue).

A negative value in BRAF-MDQ change from Baseline indicates an improvement from Baseline.

Number of Work Days Missed (Work Productivity Survey - Rheumatoid Arthritis [WPS-RA]) at Week 52Week 52

Number of work days missed in the last month for employed subjects.

Number of Days With no Household Work (Work Productivity Survey - Rheumatoid Arthritis [WPS-RA]) at Week 52Week 52

Number of days with no household work in the last month.

Number of Days With Hired Outside Help (Work Productivity Survey - Rheumatoid Arthritis [WPS-RA]) at Week 52Week 52

Number of days with hired outside help in the last month.

Number of Days Missed of Family/Social/Leisure Activities (Work Productivity Survey - Rheumatoid Arthritis [WPS-RA]) at Week 52Week 52

Number of days missed of family/social/leisure activities in the last month.

Interference With Household Work Productivity (Work Productivity Survey - Rheumatoid Arthritis [WPS-RA]) at Week 52Week 52

The Arthritis interference in the last month with household work productivity is measured on a scale that ranges from 0 (no interference) to 10 (complete interference).

Trial Locations

Locations (178)

159

🇺🇸

Los Angeles, California, United States

178

🇺🇸

Corpus Christi, Texas, United States

223

🇺🇸

Houston, Texas, United States

180

🇺🇸

Mobile, Alabama, United States

75

🇸🇪

Uppsala, Sweden

236

🇺🇸

Durham, North Carolina, United States

170

🇺🇸

Huntsville, Alabama, United States

251

🇺🇸

Tucson, Arizona, United States

257

🇺🇸

Hemet, California, United States

160

🇺🇸

Covina, California, United States

202

🇺🇸

Upland, California, United States

172

🇺🇸

Whittier, California, United States

196

🇺🇸

Jupiter, Florida, United States

201

🇺🇸

San Leandro, California, United States

238

🇺🇸

Lake Mary, Florida, United States

190

🇺🇸

Fort Lauderdale, Florida, United States

232

🇺🇸

Miami, Florida, United States

213

🇺🇸

Naples, Florida, United States

255

🇺🇸

Orlando, Florida, United States

214

🇺🇸

Ocala, Florida, United States

237

🇺🇸

Orange Park, Florida, United States

163

🇺🇸

Palm Harbor, Florida, United States

166

🇺🇸

Plantation, Florida, United States

192

🇺🇸

Sarasota, Florida, United States

244

🇺🇸

Springfield, Illinois, United States

200

🇺🇸

Vero Beach, Florida, United States

224

🇺🇸

South Bend, Indiana, United States

215

🇺🇸

Cedar Rapids, Iowa, United States

177

🇺🇸

Hagerstown, Maryland, United States

203

🇺🇸

Tupelo, Mississippi, United States

198

🇺🇸

Eagan, Minnesota, United States

179

🇺🇸

Saint Louis, Missouri, United States

256

🇺🇸

Reno, Nevada, United States

229

🇺🇸

Lebanon, New Hampshire, United States

176

🇺🇸

Brooklyn, New York, United States

207

🇺🇸

Albuquerque, New Mexico, United States

242

🇺🇸

Plainview, New York, United States

245

🇺🇸

Middleburg Heights, Ohio, United States

195

🇺🇸

Bethlehem, Pennsylvania, United States

167

🇺🇸

Duncansville, Pennsylvania, United States

168

🇺🇸

Wyomissing, Pennsylvania, United States

217

🇺🇸

Allen, Texas, United States

162

🇺🇸

Dallas, Texas, United States

185

🇺🇸

Amarillo, Texas, United States

161

🇺🇸

Austin, Texas, United States

206

🇺🇸

Houston, Texas, United States

184

🇺🇸

Houston, Texas, United States

158

🇺🇸

Mesquite, Texas, United States

175

🇺🇸

Nassau Bay, Texas, United States

249

🇺🇸

Plano, Texas, United States

233

🇺🇸

Kennewick, Washington, United States

197

🇺🇸

San Antonio, Texas, United States

174

🇺🇸

Glendale, Wisconsin, United States

183

🇺🇸

Clarksburg, West Virginia, United States

284

🇦🇷

Rosario, Argentina

291

🇦🇷

Tucuman, Argentina

6

🇦🇺

Coffs Harbour, New South Wales, Australia

2

🇦🇺

Herson, Queensland, Australia

1

🇦🇺

Maroochydore, Queensland, Australia

8

🇦🇺

Woodville South, South Australia, Australia

4

🇦🇺

Geelong, Victoria, Australia

5

🇦🇺

Fitzroy, Victoria, Australia

3

🇦🇺

Malvern, Victoria, Australia

51

🇧🇪

Brussels, Belgium

36

🇧🇪

Kortrijk, Belgium

126

🇧🇪

Gilly, Belgium

235

🇨🇦

Hamilton, Ontario, Canada

188

🇨🇦

Montreal, Quebec, Canada

293

🇨🇴

Bogota, Colombia

272

🇨🇴

Bogota, Colombia

299

🇨🇴

Bogota, Colombia

288

🇨🇴

Chia, Colombia

297

🇨🇴

Bucaramanga, Colombia

271

🇨🇴

Medellin, Colombia

34

🇫🇷

Orleans, France

124

🇨🇿

Bruntal, Czechia

108

🇨🇿

Brno, Czechia

38

🇨🇿

Hradec Kralove, Czechia

16

🇫🇷

Le Kremlin Bicetre, France

85

🇫🇷

Le Mans, France

88

🇫🇷

Montpellier Cedex 5, France

52

🇩🇪

Bad Doberan, Germany

17

🇩🇪

Bayreuth, Germany

89

🇩🇪

Erfurt, Germany

113

🇩🇪

Berlin, Germany

120

🇩🇪

Berlin, Germany

70

🇩🇪

Frankfurt, Germany

71

🇩🇪

Hamburg, Germany

81

🇩🇪

Hildesheim, Germany

114

🇩🇪

Würzburg, Germany

132

🇩🇪

Ratingen, Germany

61

🇩🇪

München, Germany

127

🇩🇪

Lingen, Germany

53

🇩🇪

Planegg, Germany

69

🇩🇪

Rheine, Germany

49

🇩🇪

Rendsburg, Germany

18

🇭🇺

Budapest, Hungary

131

🇭🇺

Szolnok, Hungary

19

🇭🇺

Veszprem, Hungary

110

🇭🇺

Szombathely, Hungary

33

🇮🇪

Cork, Ireland

281

🇲🇽

Durango, Mexico

286

🇲🇽

Guadalajara, Mexico

280

🇲🇽

Monterrey, Mexico

67

🇵🇱

Elblag, Poland

92

🇵🇱

Poznan, Poland

100

🇵🇱

Warszawa, Poland

44

🇵🇱

Wroclaw, Poland

111

🇷🇴

Bucharest, Romania

47

🇪🇸

Madrid, Spain

63

🇪🇸

Santiago de Compostela, Spain

76

🇸🇪

Göteborg, Sweden

82

🇸🇪

Huddinge, Sweden

106

🇸🇪

Lund, Sweden

77

🇸🇪

Stockholm, Sweden

118

🇨🇭

Fribourg, Switzerland

125

🇬🇧

Cannock, United Kingdom

105

🇬🇧

Dudley, United Kingdom

56

🇬🇧

Leeds, United Kingdom

121

🇬🇧

London, United Kingdom

80

🇬🇧

Sheffield, United Kingdom

119

🇬🇧

York, United Kingdom

27

🇬🇧

London, United Kingdom

191

🇺🇸

Wichita, Kansas, United States

210

🇺🇸

Wichita, Kansas, United States

7

🇦🇺

Perth, Western Australia, Australia

279

🇦🇷

San Juan, Argentina

65

🇧🇪

Yvoir, Belgium

189

🇺🇸

Charleston, South Carolina, United States

204

🇺🇸

Hendersonville, Tennessee, United States

247

🇺🇸

Glendale, Arizona, United States

165

🇺🇸

Paradise Valley, Arizona, United States

298

🇨🇴

Medellin, Colombia

205

🇺🇸

Columbia, South Carolina, United States

181

🇺🇸

Lincoln, Nebraska, United States

226

🇺🇸

Coeur d'Alene, Idaho, United States

228

🇺🇸

Clifton, New Jersey, United States

234

🇺🇸

Paradise Valley, Arizona, United States

199

🇺🇸

Kalamazoo, Michigan, United States

303

🇨🇴

Barranquilla, Colombia

54

🇮🇪

Dublin, Ireland

194

🇨🇦

Trois-rivieres, Quebec, Canada

86

🇭🇺

Eger, Hungary

22

🇷🇴

Bucharest, Romania

25

🇷🇴

Bucharest, Romania

26

🇷🇴

Bucharest, Romania

24

🇷🇴

Iasi, Romania

240

🇨🇦

Kelowna, British Columbia, Canada

32

🇮🇪

Limerick, Ireland

302

🇲🇽

Merida, Mexico

78

🇲🇨

Monaco, Monaco

128

🇵🇱

Bydgoszcz, Poland

99

🇵🇱

Krakow, Poland

74

🇵🇱

Torun, Poland

42

🇳🇱

Leiden, Netherlands

58

🇷🇴

Brasov, Romania

68

🇨🇭

St. Gallen, Switzerland

21

🇭🇺

Budapest, Hungary

292

🇲🇽

Mexico City, Mexico

294

🇲🇽

San Luis Potosi, Mexico

115

🇮🇹

Ferrara, Italy

122

🇮🇹

Milano, Italy

40

🇮🇹

Reggio Emilia, Italy

41

🇮🇹

Verona, Italy

72

🇮🇹

Roma, Italy

276

🇦🇷

Buenos Aires, Argentina

50

🇦🇹

Wien, Austria

57

🇷🇴

Lasi, Romania

37

🇨🇿

Praha, Czechia

79

🇫🇷

Strasbourg, France

93

🇪🇸

Coruna, Spain

209

🇺🇸

Birmingham, Alabama, United States

241

🇺🇸

Oklahoma City, Oklahoma, United States

243

🇺🇸

Phoenix, Arizona, United States

186

🇺🇸

Portland, Oregon, United States

123

🇸🇪

Malmö, Sweden

59

🇩🇪

Zerbst, Germany

227

🇺🇸

Rochester, New York, United States

© Copyright 2025. All Rights Reserved by MedPath